Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene

Clinical Biochemistry

Volumn 43, Issue 3, 2010, Pages 331-334

  Öfverholm, Anna ^a   Arkblad, Eva ^a,b   Skrtic, Stanko ^a   Albertsson, Per ^a   Shubbar, Emman ^a   Enerbäck, Charlotta ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Unilabs   (France)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

5 fluorouracil; Colon cancer; Dihydropyrimidine dehydrogenase; DPYD; Toxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GENOMIC DNA; MESSENGER RNA;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CASE REPORT; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EPIPHORA; FATIGUE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMICOLECTOMY; HETEROZYGOTE; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPLICING DEFECT; STOMATITIS; TREATMENT DURATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENETIC VARIATION; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA;

EID: 74449085507     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.09.024     Document Type: Article

References (13)

1. van Kuilenburg A.B., Haasjes J., Richel D.J., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6 (2000) 4705-4712
2. Van Kuilenburg A.B., Meinsma R., Zoetekouw L., and Van Gennip A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer 101 (2002) 253-258
3. Karthaus M., Rosenthal C., and Ganser A. Prophylaxis and treatment of chemo-and radiotherapy-induced oral mucositis- are there new strategies?. Bone Marrow Transplant. 24 (1999) 1095-1108
4. Grem J.L. 5-Fluoropyrimidines. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy: principles and practice. 2nd Ed. (1996), Philadelphia, PA, USA, Lippencott 149-211
5. Vreken P., Van Kuilenburg A.B., Meinsma R., et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis. 19 (1996) 645-654
6. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., and Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98 (1996) 610-615
7. Van Kuilenburg A.B., De Abreu R.A., and van Gennip A.H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem. 40 (2003) 41-45
8. Amstutz U., Farese S., Aebi S., and Largiadèr C.R. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J. Exp. Clin. Cancer Res. 27 (2008) 54
9. Maitland M.L., Vasisht K., and Ratain M.J. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. Trends Pharmacol. Sci. 27 (2006) 432-437
10. Van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40 (2004) 939-950
11. Amstutz U., Farese S., Aebi S., and Largiadèr C.R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10 (2009) 931-944
12. Gamelin E., Delva R., Jacob J., Merrouche Y., et al. Individual fluorouracil dose adjustment based on pharmacokinetics follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 13 (2008) 2099-2105
13. Walko C.M., and McLeod H.L. Will we ever be ready for blood level-guided therapy?. J. Clin. Oncol. 13 (2008) 2078-2079